GlassScriptPhysician profile
Stanley Seth Bush, III
NPI 1578500591
$1,696.27
in general payments reported to CMS, 2019-2025
21 companies · $169 in 2025
The $169 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $52.17 · 2021: $250 · 2022: $287 · 2023: $366 · 2024: $416 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $442.94 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $209.00 | 2021-2025 | Qelbree, Qelbree |
| Stryker Corporation | $128.33 | 2023-2024 | Mesa Spinal System |
| Ironshore Pharmaceuticals INC. | $109.23 | 2019-2024 | |
| Tris Pharma INC | $92.03 | 2019-2021 | |
| Pfizer INC. | $82.99 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $79.79 | 2019-2022 | |
| Seqirus USA INC | $71.77 | 2022-2025 | Flucelvax |
| Sanofi-Aventis U.S. LLC | $60.65 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.23 | 2019-2021 | |
| Glaxosmithkline, LLC. | $55.54 | 2020-2024 | Bexsero |
| Kaleo, INC. | $54.24 | 2019-2022 | |
| Sobi, INC | $48.69 | 2023 | |
| Adlon Therapeutics L.P. | $36.54 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $34.78 | 2025 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $29.08 | 2024 | Adzenys Xr-Odt |
| Mylan Pharmaceuticals INC. | $26.10 | 2021 | |
| Kyowa Kirin, INC. | $23.06 | 2024 | Crysvita |
| Qol Medical, LLC | $22.56 | 2023 | Sucraid |
| Csl Behring | $16.77 | 2025 | Hizentra |
| Aytu Biopharma, INC. | $14.95 | 2024 | Karbinal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.